CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way. That’s a real nice CRISPR cure you have there. It would be a pity if ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has made it to the major leagues in the world of biotech. The company is the leading maker of cystic fibrosis (CF) treatments, with its products generating more ...

With the first medical therapy approved and systems like CRISPR-Cas showing up in complex cells, there’s a lot happening in the genome editing field. By Amber Dance/Knowable Magazine Published Jan 26, ...

When Victoria Gray was still a baby, she started howling so inconsolably during a bath that she was rushed to the emergency room. The diagnosis was sickle-cell disease, a genetic condition that causes ...

CRISPR is in the process of a BLA for a potential breakthrough drug. The company isn't profitable and is losing its chief operating officer. CRISPR has more than $1.9 billion in cash. It opened ...

Researchers have made an important step forward toward a long-desired goal: using the gene-editing technology CRISPR to treat cancer. In a study published in Nature, scientists recruited 16 people who ...